VTRS
ViatrisViatris is a pharmaceuticals name in the health care sector. Over the past year it returned +80.5%, against +4.7% over three months and +4.0% over one. It trades 16.2% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 31.9% is above the market's typical range.
Its worst peak-to-trough decline over the year was -19.0%, and it has traded a median $144M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.29 with the S&P 500 proxy, so it has been moving substantially on its own.
How VTRS scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.
Start a free 7-day trial| 1 day | +0.1% |
| 1 week | -3.6% |
| 1 month | +4.0% |
| 3 months | +4.7% |
| 6 months | +33.4% |
| 1 year | +80.5% |
| 12-1 momentum | +73.6% |
| Volatility (1y, annualized) | 31.9% |
| Max drawdown (1y) | -19.0% |
| Distance vs 200-day average | +16.2% |
| Return per unit of risk | 2.52 |
| Median daily dollar volume | $144M |
Get VTRS when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.